• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Geron Corporation

    2/13/24 5:06:14 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GERN alert in real time by email
    SC 13G 1 tv01013-geroncorp.htm SCHEDULE 13G geroncorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  Geron Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  374163103

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  374163103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    777,572

    7.  SOLE DISPOSITIVE POWER

    27,406,319

    8.  SHARED DISPOSITIVE POWER

    1,158,255

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,564,574

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.26%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Geron Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    919 East Hillsdale Boulevard, Suite 250
    Foster City, CA 94404

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    374163103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $GERN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GERN

    DatePrice TargetRatingAnalyst
    7/10/2025$1.00Sell
    Goldman
    5/8/2025$1.50Sector Outperform → Sector Perform
    Scotiabank
    2/27/2025$3.50 → $2.00Buy → Neutral
    B. Riley Securities
    2/26/2025Buy → Neutral
    H.C. Wainwright
    11/5/2024$8.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$7.00Outperform
    Leerink Partners
    4/30/2024$4.50Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $GERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lawlis V Bryan bought $15,667 worth of shares (13,300 units at $1.18) (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      5/13/25 4:20:43 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Legal Officer Samuels Scott Alan bought $24,150 worth of shares (15,000 units at $1.61), increasing direct ownership by 128% to 26,682 units (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      3/3/25 6:01:08 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, President and CEO Scarlett John A bought $22,062 worth of shares (12,500 units at $1.76) (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      3/3/25 6:01:06 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,116,000 shares of its common stock, consisting of stock options to purchase an aggregate of 744,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 372,000 shares of common stock, to 16 newly hired employees as an inducement material to their acceptance of employment with Geron. The stock options and RSUs were granted on June 17, 2025. The stock options have an exercise price of $1.45 per share, which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and

      6/18/25 4:10:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

      New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum erythropoietin (sEPO) level, or prior therapy use Health-related quality-of-life (QOL) data and results on time without transfusion reliance (TWiTR) provide deeper insights into patient-centric outcomes with RYTELO in LR-MDS Updates on ongoing IMpactMF and IMproveMF trials of imetelstat show progress in advancing the science of telomerase inhibition in the treatment of myelofibrosis Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by cha

      5/28/25 8:30:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 137,000 shares of common stock, to six newly hired employees as an inducement material to their acceptance of employment with Geron. The stock options and RSUs were granted on May 16, 2025. The stock options have an exercise price of $1.27 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year term and vest

      5/19/25 4:15:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spiegel Robert J. was granted 5,540 shares, increasing direct ownership by 3% to 182,844 units (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      7/1/25 4:53:59 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aggarwal Gaurav

      4 - GERON CORP (0000886744) (Issuer)

      5/22/25 5:07:35 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Interim President and CEO Bir Dawn Carter

      4 - GERON CORP (0000886744) (Issuer)

      5/22/25 5:06:38 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman resumed coverage on Geron with a new price target

      Goldman resumed coverage of Geron with a rating of Sell and set a new price target of $1.00

      7/10/25 8:55:29 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron downgraded by Scotiabank with a new price target

      Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50

      5/8/25 8:26:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously

      2/27/25 6:20:37 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 7, 2024 - FDA Roundup: June 7, 2024

      For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

      6/7/24 3:46:22 PM ET
      $GERN
      $SRAX
      $SNAP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Advertising
      Consumer Discretionary
    • FDA Approval for RYTELO issued to GERON CORP

      Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

      6/7/24 12:36:59 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    SEC Filings

    See more
    • SEC Form S-8 filed by Geron Corporation

      S-8 - GERON CORP (0000886744) (Filer)

      6/30/25 5:04:21 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GERON CORP (0000886744) (Filer)

      5/27/25 4:26:47 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Geron Corporation

      SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)

      5/15/25 4:57:13 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Leadership Updates

    Live Leadership Updates

    See more
    • Geron Corporation Announces Departure of Chief Executive Officer

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development

      3/11/25 4:02:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving innovative medical and scientific strategies that support RYTELO™ commercially and sustain important research and development opportunities for Geron. Dr. Eid has more than two decades of medical affairs, clinical development, and drug life-cy

      11/11/24 4:30:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegler has more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations. "Jim brings to Geron an impressive track record of operationa

      9/9/24 4:15:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Financials

    Live finance-specific insights

    See more
    • Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026 Company to host conference call and webcast today, May 7 at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial

      5/7/25 7:00:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and business highlights before the market opens on Wednesday, May 7, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website for 30 days. Participants m

      3/31/25 4:30:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated tre

      2/26/25 7:30:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 5:46:12 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 9:31:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Geron Corporation

      SC 13G - GERON CORP (0000886744) (Subject)

      11/14/24 6:25:29 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care